Telix Pharmaceuticals has partnered with Subtle Medical to integrate AI-powered technology into its PET imaging processes.
The collaboration focuses on using Subtle Medical's SubtlePET™ software, which has FDA clearance and can reduce PET scan times by up to 75% without compromising image quality.
This integration is expected to enhance patient experiences by minimizing wait times and reducing the duration patients must remain motionless during scans.
The integration of AI technology into Telix's imaging processes allows medical facilities to optimize workflows and resource utilization.
It also aligns with trends in the healthcare sector that prioritize patient-centric solutions and operational efficiency.
The initial target market for this partnership is the U.S., with plans to expand to other regions pending regulatory approvals.
This partnership underscores the growing importance of technological innovation in the biopharmaceutical industry, particularly in oncology and rare diseases.
Telix Pharmaceuticals is committed to expanding its portfolio of products, and the integration of AI into its imaging solutions is expected to play a crucial role in its strategic vision.